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Background: Lung cancer is the leading cause of cancer death and 
a major public health challenge across the entire world. Computed 
tomography (CT) imaging of the lung is a rapidly improving medical 
imaging technique. Spiral CT has been reported to not only improve 
the early detection of lung cancer in screening high-risk tobacco-
exposed populations but also to assist in the clinical assessment of 
new agents for therapy in lung cancer.
Methods: The Prevent Cancer Foundation has sponsored a series 
of workshops to accelerate progress in using quantitative imaging 
to advance lung cancer research progress, of which this report sum-
marizes the Ninth Workshop. The defining strategy of this forum 
to support innovation in quantitative research for early lung cancer 
management was to enable software validations by assembling col-
lections of high-quality images for which long-term clinical follow-
up is known.  An additional approach was to define a process for 
high-quality and economical national implementation of lung cancer 
screening. Representatives from the Quantitative Imaging Biomarker 
Alliance, the International Association for the Study of Lung Cancer, 
the Lung Cancer Alliance, and other organizations outlined their 
efforts in this regard. A major opportunity exists to advance the dia-
logue on the use of quantitative imaging tools to cross-fertilize and 
accelerate image-processing research across lung cancer and chronic 
obstructive pulmonary disease (COPD).
Conclusion: The use of high-resolution CT imaging provides a win-
dow into a much earlier stage of COPD as well as coronary artery 
disease, both being tobacco-induced diseases. Progress in this area 
was reviewed and opportunities for enhanced collaborative progress 
defined. Key sessions reviewed emerging developments with imaging 
technology and the infrastructure to support the storage and distribu-
tion of these high-content modalities. Cooperation among diverse 
collaborators is essential to enable the rapid organic evolution of this 
field, so that improved outcomes with lung cancer, artery disease, and 
COPD can be obtained.
Key Words: Lung cancer, Image processing, Quantitative imag-
ing, Low-dose computed tomography screening, Imaging response 
marker
(J Thorac Oncol. 2013;8: 1352–1355)
The Ninth Prevent Cancer Foundation Workshop was held on May 3 and 4 in Hyattsville, Maryland, to explore 
current opportunities to advance the integration of quanti-
tative computed tomography (CT) imaging for evaluation 
of early lung cancer. This forum has been a catalytic influ-
ence in advancing the integration of quantitative CT imaging 
for evaluation of early lung cancer. The meeting has been 
conducted as a precompetitive workshop and has convened 
a diverse interdisciplinary group of leaders in imaging sci-
ences, drug development, clinical research, federal regula-
tors, scientists and patient advocates. The convener of this 
forum over the last 9 years has been the advocacy founda-
tion, the Prevent Cancer Foundation working with other 
institutions such as the Optical Society of America. For this 
Workshop, the International Association of the Study of 
Lung Cancer was also a sponsor. This primary goal of this 
Workshop series is to provide a forum for cross-disciplinary 
discussion and plan the development of strategies that allow 
for more rapid progress.
To open the meeting, Dr. James Mulshine of Rush 
University reviewed the current status of this field, outlin-
ing the four major rationales for this forum. This includes 
that lung cancer is the leading cause of cancer death and a 
major public health challenge across the entire world. The 
resolution and speed of CT imaging of the lung is rapidly 
improving. Further, a single, state-of-the-art CT imaging 
study acquires vastly more data than can be manually pro-
cessed for application to routine clinical management and so 
further development of software especially to assist in quanti-
tative clinical assessments is required. Finally, although there 
have been some incremental successes, drug development for 
lung cancer needs to be greatly improved both to better help 
patients and to allow continued investment from the pharma-
ceutical industry.
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Early on, Workshop participants had identified the stra-
tegic need for high-quality, high-resolution imaging databases 
associated with clinical outcomes as an essential resource to 
enable progress in this field. The Prevent Cancer Foundation 
efforts have included initiating a dialogue with the National 
Cancer Institute, which led to the development of their Lung 
Imaging Database Consortium and the underwriting of estab-
lishing an early open, lung CT image database in collabora-
tion with imaging researchers at Cornell.1
The Foundation also encouraged the dialogue between 
the academic thoracic community and the leadership of 
glaxoSmithKline to complete the first thoracic, phased II neo-
adjuvant, window-of-opportunity trial evaluating the activ-
ity of paxopanib in untreated lung cancer using quantitative 
CT imaging. The published Phase II neoadjuvant, window-
of-opportunity clinical trial led by Altorki2 using the drug 
pazopanib demonstrated how quantitative imaging can be 
integrated with molecular diagnostics to enhance information 
yield. This trial approach provides in-depth mechanistic feed-
back about the results of exposure of untreated lung cancer to 
the experimental drug. The integration of results before and 
after tissue sampling and primary tumor imaging evaluations 
in relation to drug exposure provides a critical opportunity to 
more fully define the behavior of the molecular target in the 
primary tumor tissue.
Using Imaging to Support Innovative 
New Trial Structures
If neoadjuvant window trials are done routinely with all 
new lung cancer drugs, systematic analysis of this aggregated 
information would accelerate our understanding of the molec-
ular underpinning of lung cancer. This trial strategy would 
also aid in identifying appropriate companion diagnostics for 
specific targeted molecules to indicate the success or failure of 
the drug exposure. This detailed response assessment on the 
effect of the targeted agents on untreated, early lung cancer 
cohort is a key direction in the development of science-based 
strategies for lung cancer therapy. From a drug-development 
perspective, this approach may also shorten the time to market 
a new drug. This may be particularly true if the applications 
are focused on early disease management, such as with adju-
vant or neoadjuvant therapy, similar to what is happening in 
early breast cancer management.
According to the Center for Disease Control (CDC), 
smoking accounts for U.S. $167 billion annually in health care 
expenditures, with a significant fraction of those costs related 
to lung cancer. With the aging of the U.S. population, the total 
number of annual lung cancer cases is expected to rise by 50% 
over the next two decades.3 Yet there are also favorable dynam-
ics such as with the rapid improvement of CT imaging of the 
lung. In addition, there is more interest in the development of 
software to assist in evaluating high-resolution imaging stud-
ies of the lung, even with brief duration of drug exposure. The 
image archives of such studies, along with growing collec-
tions of lung images linked to clinical outcome will facilitate 
the validation of robust quantitative imaging tools.
The challenge is that the lung is an extremely com-
plex anatomic structure surrounded by other complex 
structures and early lung cancers emerge in a wide variety 
of shapes and textures. Nevertheless, quantitative CT imag-
ing is being used in lung cancer drug trials (such as with 
the pazopanib experience) as well as in early lung cancer 
detection trials.
During the previous eight Workshops, participants 
have contributed not only to these types of clinical trials 
activities, but to the development of lung imaging data-
bases, publications around the developmental challenges 
in this field, and the development of open-source quantita-
tion tools. There has also been work on software evaluation 
using a challenge mechanism to advance the acceptance of 
quantitative imaging as a formal tool to apply in Food and 
Drug Administration regulatory settings. In this context, 
many of the participants in this Workshop also participate 
in the Radiological Society of North America’s Quantitative 
Imaging Biomarker Alliance (QIBA).4 The QIBA pursues 
the broader vision of developing all major medical imaging 
platforms for quantitative applications, whereas the goal of 
the Workshop has remained focused on CT imaging in lung 
cancer. A positive collaboration has emerged because lung 
CT is one of the more rapidly evolving areas of quantitative 
imaging and the Workshop brings a strong clinical applica-
tion orientation to the effort.4 Both QIBA and the Workshop 
share an interest in defining the sources of variance in 
CT-based quantitative imaging and then finding strategies to 
overcome such variances.
Approach to Improve Imaging Innovation
A shared interest of Workshop participants is in advanc-
ing quantitative CT-based lung imaging toward defining the 
most efficient and meaningful application of this approach 
to objectively demonstrate the unique value of quantitative 
CT imaging to improve lung cancer clinical management. 
Most of the focus on validating quantitative CT in the lung 
has been on lung cancer therapeutics. However, two recent 
developments provide an alternative to consider. In a Dutch–
Belgian randomized trial of CT-based lung cancer screen-
ing (NELSON), the use of quantitative CT to evaluate for 
growth in a suspicious nodule was associated with accurate 
and efficient detection of clinically significant lung cancers.5 
This finding becomes even more significant with the National 
Cancer Institute’s recent report on the results of the National 
Lung Screening Trial’s finding of a 20% mortality reduc-
tion benefit from CT-based lung cancer screening associated 
with generally favorable clinical management outcomes.6 
Although to date there has been no consensus on how to most 
efficiently conduct imaging with lung cancer screening, hav-
ing a robust quantitative imaging measurement tool to find 
rapidly growing solid lung nodules would be a great benefit. 
Therefore, defining a process on how to objectively validate 
such an application is also an important topic for Workshop 
discussion.
Therefore, there are two major applications that pro-
vide significant opportunities for quantitative imaging vali-
dation: one with drug development and the other with lung 
cancer screening diagnostic workup. In both these areas, to 
develop, refine, and then validate robust performance, the 
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outstanding need is for a large number of clinical cases in 
which the CT image files are available and linked with long-
term clinical outcome. This need for outcomes data is critical 
to define the actual objective performance of candidate image 
measurement tools. A strategic focus of this Workshop is to 
consider the challenges entailed in advancing either of these 
two validations. A further issue is to consider how the image 
resources for one study can be pooled to advance the valida-
tion of the other. For instance with the three largest screen-
ing trials, the National Lung Screening Trial, NELSON, and 
the International Early Lung Cancer Action Project, there are 
more than 90,000 cases of serial CT images for which clinical 
outcome is known.5–7 These data form a profoundly valuable 
public health resource as a validation matrix and could greatly 
accelerate the development of precise quantitative imaging 
measurement tools.
Large Screening Data Sets and Rapid Learning
The integration of quantitative imaging tools is facili-
tated by the emergence of electronic medical records, allow-
ing imaging information to be integrated with other sources 
of information about patient management. The Institute of 
Medicine has published a series of reports discussing how to 
use large data sets to allow for continuous process improve-
ment, which it describes as the Rapid Learning Healthcare 
System. This approach of aggregating large clinical data sets 
not only provides a strategic opportunity for further improv-
ing quantitative tools, but also focuses attention on the strate-
gic challenge of holding back both quantitative imaging and 
rapid learning. In advancing both these approaches, there is a 
critical need for the routine donation of clinical images and 
the associated clinical follow-up information. As was dis-
cussed with the Rapid Learning Healthcare System, there is 
a need for large databases to allow for the development of 
evidence-based clinical management and corresponding need 
for database aggregation and data mining tools.8 To support 
this, there is a need to communicate the importance of dona-
tion of clinical data and to cultivate in the public an awareness 
of the need for routine data donation. Educating the public 
as to the importance of clinical data and imaging donation to 
advance research is an important challenge. Progress in this 
effort is essential to enable the rapid development of quantita-
tive imaging. Communication of this challenge to the public 
is an important issue to consider in the Workshop Breakout 
sessions.
This Workshop will consider issues both with compu-
tational imaging and targeted drug development, with a goal 
of fostering progress in the capability to successfully man-
age early lung cancer. We will also work to refine strategies 
to integrate computational imaging in drug development 
for lung cancer or for the related tobacco-induced lung dis-
ease, COPD. We will again visit issues related to the more 
rapid development of software tools to allow accurate serial 
measurement of lung nodules in large part by supporting the 
creation of more effective image/data archives.9 We will also 
consider strategies to accelerate progress and discuss shared 
approaches with the advocacy community to communicate the 
benefit of quantitative imaging.
CONCLUSIONS
In conclusion, two compelling clinical applications exist 
for integrating quantitative CT imaging into the management 
of early lung cancer, including CT-based screening for early 
lung cancer detection and using quantitative imaging for drug 
development. There are growing numbers of serial CT image/
clinical outcome cases that are available as archival resources 
over the Web. However, the number of useful, high-resolution 
cases is still modest. This limitation greatly constrains prog-
ress in the field, especially around the development of robust 
software tools. As recently outlined by the National Research 
Council renewed efforts are needed to encourage great imag-
ing case donations, so that the aggregate size of this resource 
grows quickly.9
The use of quantitative CT imaging in the diagnostic 
evaluation of suspicious cases of screen-detected lung cancer 
is an example using volume growth criteria as measured by 
CT image process serving as a surrogate of clinically aggres-
sive cancer. This approach has been recently published in a 
report on diagnostic workups within the ongoing NELSON 
randomized screening trial. Interval nodule growth as initially 
reported by Yankelevitz and coworkers11 is an important filter 
to minimize overdiagnosis bias associated with CT-based lung 
cancer screening, which is a major advance for cancer screen-
ing as it can reduce both the cost and the morbidity of cancer 
screening management.
There is an opportunity in developing these applica-
tions in parallel, because the CT imaging cases from either 
the drug development or the screening case detection can be 
aggregated and used to cross-validate software for either of 
the two target applications. As discussed in the Workshop 
there are other measures to improve the performance of 
quantitative imaging; for example, the use of imaging phan-
toms with quantitative CT provides a crucial opportunity to 
determine sources of measurement variance associated with 
CT imaging. Further dialogue is important to determine 
what phantom construct can enable higher-quality CT imag-
ing for lung cancer clinical management. Ongoing collabo-
ration is essential in the rapid development of this field, and 
this Workshop series continues to be a forum for proactive 
strategic planning and for helping to develop corresponding 
educational tools to help clinicians with these important and 
complex new issues.
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